Ann Surg Oncol (2018) 25:2127–2128 https://doi.org/10.1245/s10434-018-6544-0 ED ITORIA L – G A STROI N TESTIN A L O NCOL OG Y Future Treatment Strategy for Esophageal Cancer Based on Prediction of Systemic Recurrence: Signiﬁcance of Pathologic Nodal Status After Neoadjuvant Chemotherapy Takushi Yasuda, MD Department of Surgery, Faculty of Medicine, Kindai University, Osaka-Sayama, Osaka , Japan The main goals of neoadjuvant therapy are to increase A review of the role and position of chemotherapy in the curative resection rate by downstaging the primary multimodality therapy would be timely. The ﬁndings of tumor and to improve postoperative survival by eliminating several randomized clinical studies comparing neoadjuvant systemic micrometastases. Chemoradiotherapy (CRT), the CRT and NAC are currently under way and will provide mainstay of preoperative therapy for advanced esophageal some guidance in this regard. cancer in Western countries, has dramatically improved Chemotherapy is the only treatment method that can be local control by increasing the R0 resection rate. However, used to control the systemic spread of esophageal cancer. distant metastasis is common, and two recent randomized However, systemic micrometastases cannot always be clinical studies comparing neoadjuvant CRT and neoadju- eliminated by two or three courses of NAC, and vant chemotherapy (NAC)
Annals of Surgical Oncology – Springer Journals
Published: May 29, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera